Lip leishmaniasis: evaluation of 20 patients

Yıl 2019, Cilt: 2 Sayı: 4, 95 - 99, 29.12.2019

İsa An , Mustafa Aksoy , Murat Ozturk , Nebiye Yentur Doni Erhan Ayhan

https://doi.org/10.33204/mucosa.633199

Cited By: 3

Öz

Objective Mucosal leishmaniasis (ML) is an important public health problem because it has a significant morbidity and mortality rate in undeveloped countries. In this study, clinical features of patients diagnosed with ML in Sanliurfa, an endemic region for leishmaniasis, were evaluated.

Methods In this retrospective study, patients admitted to the skin and venereal diseases clinics of two different training and research hospitals between May 2015 and September 2019 and diagnosed as ML by microscopic examination were included.

Results In this study, 446 patients with CL were retrospectively evaluated and 24 lesions of 20 patients with lip involvement were included. Of the 20 patients included in the study, 11 (55%) were male and 9 (45%) were female. Lesions were seen only in the lips in 15 (75%) patients, while additional skin involvement was present in 5 (25%) patients. None of the patients had gingival or genital involvement.

Conclusion In conclusion, ML should be considered when treatment resistant lesions develop in the labial region of the patients living in endemic areas or travelling to endemic areas and the diagnosis should be confirmed and treated early.

Anahtar Kelimeler

cutaneous leishmaniasis, mucosal leishmaniasis, lip

Dudakta leishmaniasis: 20 hastanın değerlendirilmesi

Öz

Amaç Mukozal leishmaniasis (ML) gelişmemiş ülkelerde önemli bir morbidite ve mortalite oranına sahip olduğu için önemli bir halk sağlığı sorunudur. Bu çalışmada leishmaniasis için endemik bir bölge olan Şanlıurfa ilinde ML tanısı konulan hastaların klinik özellikleri değerlendirildi.

Yöntem Bu retrospektif çalışmamıza, iki ayrı eğitim ve araştırma hastanesinin deri ve zührevi hastalıkları kliniğine Mayıs 2015- Eylül 2019 tarihleri arasında başvuran ve mikroskobik incelemeyle ML tanısı konulan hastalar dahil edildi.

Bulgular Çalışmamızda 446 KL hastası retrospektif olarak incelendi, dudak mukozası tutulumu olan 20 hastanın 24 lezyonu dahil edildi. Çalışmaya katılan 20 hastanın 11‘i (%55) erkek, 9’u (%45) kadındı. 15(%75) hastada lezyonlar sadece dudaklarda görülürken, 5(%25) hastada ayrıca deri tutulumu da mevcuttu. Hiçbir hastada diş eti tutulumu ve genital bölge tutulumu yoktu.

Sonuç Sonuç olarak leishmaniasis için endemik olan bölgelerde yaşayan veya bu bölgelere seyahat eden kişilerde dudak bölgesinde tedaviye dirençli lezyonlar geliştiğinde ML düşünülmeli ve hastalığın tanısı doğrulanıp erken dönemde tedavi edilmelidir.

Anahtar Kelimeler

dudak, kutanöz leishmaniasis, mukozal leishmaniasis

Kaynakça

• 1. Harman M. Cutaneous Leishmaniasis. Turk J Dermatol 2015;9:168-76.
• 2. An I, Harman M, Cavus I, et al. The diagnostic value of lesional skin smears performed by experienced specialist in cutaneous leishmaniasis and routine microbiology laboratory. Turk J Dermatol 2019;13:1-5.
• 3. An I, Harman M, Esen M, et al. The effect of pentavalent antimonial compounds used in the treatment of cutaneous leishmaniasis on hemogram and biochemical parameters. Cutan Ocul Toxicol 2019;38:294-7.
• 4. Aksoy M, Yesilova A, Yesilova Y, et al. Determination factors of affecting the risks of non-recovery in cutaneous leishmaniasis patients using binary logistic regression. Ann Med Res 2018;25:530-5.
• 5. Uzun S, Gurel MS, Durdu M, et al. Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in Turkey. Int J Dermatol 2018;57:973-82.
• 6. Eroglu N, An I, Aksoy M. Dermoscopic features of cutaneous leishmaniasis lesions. Turk J Dermatol 2019;13:103-8.
• 7. Goto H, Lauletta Lindoso JA. Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am 2012;26:293-307.
• 8. Ibrahim M, Suliman A, Hashim FA, et al. Oronasal leishmaniasis caused by a parasite with an unusual isoenzyme profile. Am J Trop Med Hyg1997;56:96-8.
• 9. Abbas K, Musatafa MA, Abass S, et al. Mucosal leishmaniasis in a Sudanese patient. Am J Trop Med Hyg 2009;80:935-8.
• 10. Kharfi M, Fazaa B, Chaker E, Kamoun MR. Mucosal localization of leishmaniasis in Tunisia: 5 cases. Ann Dermatol Venereol 2003;130:27-30.
• 11. Pace D. Leishmaniasis. Journal of Infection 2014;69:10-8.
• 12. El-Hoshy K. Lip leishmaniasis. J Am Acad Dermatol 1993; 28:661-2.
• 13. Sitheeque MA, Qazi AA, Ahmed GA. A study of cutaneous leishmaniasis involvement of the lips and perioral tissues. Br J Oral Maxillofac Surg 1990;28:43-6.
• 14. Yesilova Y, Aksoy M, Surucu HA, et al. Lip leishmaniasis: Clinical characteristics of 621 patients. Int J Crit Illn Inj Sci 2015;5:265-6.
• 15. Roundy S, Almony J, Zislis T. Cutaneous Leishmaniasis of the lower lip in a united states soldier. J Oral Maxillofac Surg 2008;66:1513-5.
• 16. Ferreli C, Atzori L, Zucca M, Pistis P, Aste N. Leishmaniasis of the lip in a patient with Down’s syndrome. J Eur Acad Dermatol Venereol 2004;18:599-602.
• 17. Veraldi S, Rigoni C, Gianotti R. Leishmaniasis of the lip. Acta Derm Venereol 2002;82:469-70.
• 18. Veraldi S, Bottini S, Persico MC. Case report: leishmaniasis of the upper lip. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:659-61.
• 19. Motta ACF, Lopes MA, Ito FA, Carlos-Bregni R, De Almeida OP, Roselino AM. Oral leishmaniasis: a clinicopathological study of 11 cases. Oral Dis 2007;13:335-40.
• 20. Mohammadpour I, Motazedian MH, Handjani F, Hatam GR. Lip leishmaniasis: a case series with molecular identification and literature review. BMC Infect Dis 2017;17:96.
• 21. Grave B, McCullough M, Wiesenfeld D. Orofacial granulomatosis: a 20-year review. Oral Dis 2009;15:46-51.
• 22. De Paulo LF, Rocha GF, Luisi Jr CM, Rosa RR, Durighetto Jr AF. Mucocutaneous leishmaniasis: mucosal manifestations in an endemic country. Int J Infect Dis 013;17:1088-9.
• 23. Strazzulla A, Cocuzza S, Pinzone MR, et al. Mucosal leishmaniasis: an underestimated presentation of a neglected disease. Biomed Res Int 2013;2013:805108.
• 24. Esmann J. The many challenges of facial herpes simplex virus infection. J Antimicrob Chemother 2001;47:17-27.
• 25. Saab J, Fedda F, Khattab R, et al. Cutaneous leishmaniasis mimicking inflammatory and neoplastic processes: a clinical, histopathological and molecular study of 57 cases. J Cutan Pathol 2012;39:251-62.
• 26. Culha G, Uzun S, Ozcan K, et al. Comparison of conventional and polymerase chain reaction diagnostic techniques for leishmaniasis in the endemic region of Adana, Turkey. Int J Dermatol 2006;45:569-72.
• 27. Sellheyer K, Haneke E. Protozoan diseases and parasitic infestations. In: Elder DE, editor. Lever’s histopathology of the skin. 9th ed. Philadelphia: Lippincott 2005. p.635-9.
• 28. Goto H, Lindoso JAL. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010;8:419-33.
• 29. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop 2008;105:1-9.
• 30. Monge-Maillo B, Lopez-Velez R. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous Leishmaniasis. Drugs 2013;73:1889-920.